• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    12/27/23 2:11:57 PM ET
    $ACNT
    $ADD
    $ARBB
    $ASST
    Steel/Iron Ore
    Industrials
    Engineering & Construction
    Consumer Discretionary
    Get the next $ACNT alert in real time by email

    Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per share.

    Reneo Pharmaceuticals shares climbed 13.6% to $1.59 on Wednesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • First Wave BioPharma, Inc. (NASDAQ:FWBI) shares jumped 169% to $9.90 after the company announced that it entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases.
    • Cingulate Inc. (NASDAQ:CING) gained 95.2% to $4.08.
    • RiskOn International, Inc. (NASDAQ:ROI) shares climbed 91.8% to $0.27. RiskOn International expects to announce its new generative AI platform and technology partner on Jan. 3, 2024.
    • Cytokinetics, Incorporated (NASDAQ:CYTK) surged 64.2% to $75.05 after the company announced topline results from SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    • AEye, Inc. (NASDAQ:LIDR) rose 61.2% to $3.58.
    • Vince Holding Corp. (NYSE:VNCE) jumped 42% to $3.2399.
    • Bit Brother Limited(NASDAQ:BETS) gained 38.2% to $0.0152 after jumping 111% on Tuesday.
    • Nxu, Inc. (NASDAQ:NXU) rose 34% to $4.18.
    • Virax Biolabs Group Limited (NASDAQ:VRAX) gained 32% to $1.7551.
    • Jet.AI Inc. (NASDAQ:JTAI) shares gained 28% to $2.05 after falling 39% on Tuesday.
    • Elicio Therapeutics, Inc. (NASDAQ:ELTX) jumped 25% to $8.89. Elicio Therapeutics 10% owner GKCC, LLC acquired a total of 1,213,000 shares an average price of $5.81.
    • Matinas BioPharma Holdings, Inc. (NASDAQ:MTNB) gained 24.7% to $0.2518 after the company announced results from a series of in vivo studies demonstrating oral delivery of two LNC-formulated small single-strand oligonucleotides.
    • Coherus BioSciences, Inc. (NASDAQ:CHRS) shares rose 23.8% to $2.70 after the company reported the FDA approval of UDENYCA ONBODY for pegfilgrastim-cbqv.
    • TeraWulf Inc. (NASDAQ:WULF) gained 21.3% to $2.6950 after gaining 3% on Tuesday.
    • Jiuzi Holdings, Inc. (NASDAQ:JZXN) rose 15.2% to $0.7322.
    • Burford Capital Limited (NYSE:BUR) gained 14.3% to $15.44.
    • Edgewise Therapeutics, Inc. (NASDAQ:EWTX) climbed 13.8% to $10.84.
    • Mobile Global Esports Inc. (NASDAQ:MGAM) shares rose 13.8% to $0.4380 after gaining 33% on Tuesday.
    • Wheels Up Experience Inc. (NYSE:UP) gained 12.8% to $4.74.
    • Organogenesis Holdings Inc. (NASDAQ:ORGO) surged 12.2% to $4.4550. BTIG maintained Organogenesis with a Buy and raised the price target from $4 to $6.
    • Ascent Industries Co. (NASDAQ:ACNT) rose 11.9% to $9.05 as the company reported the sale of the business of Specialty Pipe & Tube for around $55 million in an all-cash deal.
    • Mynd.ai, Inc. (NYSE:MYND) gained 10.4% to $5.20.
    • Coinbase Global, Inc. (NASDAQ:COIN) surged 7.4% to $184.89.
    • Li Auto Inc. (NASDAQ:LI) gained 5.1% to $36.20.

    Losers

    • Hallmark Financial Services, Inc. (NASDAQ:HALL) shares fell 31.4% to $1.0764. Hallmark Financial Services gave notice to Nasdaq of intention to voluntarily delist its shares of common stock from Nasdaq Global Market.
    • Baosheng Media Group Holdings Limited (NASDAQ:BAOS) fell 29.5% to $4.1050.
    • Nukkleus Inc. (NASDAQ:NUKK) shares fell 28.8% to $2.60 after jumping around 11% on Tuesday.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) fell 20.4% to $7.07 after the FDA placed a clinical hold on the IOV-LUN-202 trial in response to a recently reported Grade 5 adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.
    • Mobix Labs, Inc. (NASDAQ:MOBX) shares fell 17.1% to $5.80 after surging over 34% on Tuesday.
    • Color Star Technology Co., Ltd. (NASDAQ:ADD) dipped 15.4% to $0.33.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 15.4% to $2.20. Bluejay Diagnostics announced initiation of multicenter clinical study evaluating symphony IL-6 in sepsis patients.
    • Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG) declined 15% to $0.7880.
    • ARB IOT Group Limited (NASDAQ:ARBB) fell 14.4% to $2.2155 after surging 175% on Tuesday.
    • Asset Entities Inc. (NASDAQ:ASST) declined 13.7% to $0.6120.
    • Volcon, Inc. (NASDAQ:VLCN) fell 12.7% to $0.1224. On Dec 19, Volcon got deficiency letter from Nasdaq that the company did not meet minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
    • Smart for Life, Inc. (NASDAQ:SMFL) shares fell 10.8% to $1.63 after declining 7% on Tuesday.
    • Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares fell 9.1% to $0.2090. Brainstorm Cell Therapeutics shares gained 16% on Tuesday after the company announced that it was granted patents for Allogeneic Exosome Platform-Product in neurological disorder treatments.
    • Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) shares fell 8.7% to $1.16. Inspira Technologies shares gained 5% on Tuesday after the company announced 95% accuracy results for HYLA Blood Sensor. Additionally, the company plans FDA submission for clearance in 2024.
    • InnSuites Hospitality Trust (NYSE:IHT) fell 8.6% to $1.4250.
    • Oncternal Therapeutics, Inc. (NASDAQ:ONCT) shares fell 6.8% to $0.5510. Oncternal Therapeutics updated the status of a recent study involving a treatment for relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR-T treatment.
    • Canopy Growth Corporation (NASDAQ:CGC) fell 6.2% to $5.31.

     

    Now Read This: Amazon, Adobe And 2 Other Stocks Insiders Are Selling

    Get the next $ACNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACNT
    $ADD
    $ARBB
    $ASST

    CompanyDatePrice TargetRatingAnalyst
    Strive Inc.
    $ASST
    3/10/2026$12.00Buy
    B. Riley Securities
    Elicio Therapeutics Inc.
    $ELTX
    3/10/2026$17.00Buy
    Rodman & Renshaw
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Burford Capital Limited
    $BUR
    2/20/2026$14.00Outperform
    Wedbush
    Burford Capital Limited
    $BUR
    2/18/2026Buy
    BofA Securities
    Coinbase Global Inc.
    $COIN
    2/12/2026$120.00Buy → Neutral
    Monness Crespi & Hardt
    TeraWulf Inc.
    $WULF
    2/9/2026$37.00Overweight
    Morgan Stanley
    Li Auto Inc.
    $LI
    2/9/2026$14.00Neutral → Underweight
    Analyst
    More analyst ratings

    $ACNT
    $ADD
    $ARBB
    $ASST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACNT
    $ADD
    $ARBB
    $ASST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bucella Michael C. bought $19,950 worth of shares (1,338 units at $14.91), increasing direct ownership by 0.49% to 273,552 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/13/26 5:49:13 PM ET
    $WULF
    EDP Services
    Technology

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 5:45:41 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACNT
    $ADD
    $ARBB
    $ASST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bucella Michael C. bought $19,950 worth of shares (1,338 units at $14.91), increasing direct ownership by 0.49% to 273,552 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/13/26 5:49:13 PM ET
    $WULF
    EDP Services
    Technology

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CSO Silva Raul R. was granted 4,526 shares and covered exercise/tax liability with 1,828 shares, increasing direct ownership by 139% to 4,645 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/11/26 8:13:31 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACNT
    $ADD
    $ARBB
    $ASST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Event-driven primary disease-free survival ("DFS") analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC") is anticipated in 1H 2026Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes.Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS analysis in 1H 2026 BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of n

    3/12/26 4:05:00 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

    ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, which will take place May 18–21, 2026 in Atlanta, Georgia. The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU). The analysis evalu

    3/12/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Li Auto Inc. Announces Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Quarterly total revenues reached RMB28.8 billion (US$4.1 billion)1Quarterly deliveries were 109,194 vehiclesFull year total revenues reached RMB112.3 billion (US$16.1 billion)Full year deliveries were 406,343 vehicles BEIJING, China, March 12, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced its unaudited financial results for the quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter of 2025 and Full Year 2025 Total deliveries for the fourth quarter of 2025 were 109,194 vehicles, representing a 31.2% year-over-year decrease.              FY 2025

    3/12/26 4:30:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    $ACNT
    $ADD
    $ARBB
    $ASST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Strive with a new price target

    B. Riley Securities initiated coverage of Strive with a rating of Buy and set a new price target of $12.00

    3/10/26 8:42:37 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Rodman & Renshaw initiated coverage on Elicio Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Elicio Therapeutics with a rating of Buy and set a new price target of $17.00

    3/10/26 8:40:26 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACNT
    $ADD
    $ARBB
    $ASST
    SEC Filings

    View All

    Jet.AI Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Jet.AI Inc. (0001861622) (Filer)

    3/13/26 4:05:31 PM ET
    $JTAI
    Transportation Services
    Consumer Discretionary

    SEC Form S-8 filed by Elicio Therapeutics Inc.

    S-8 - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/12/26 4:39:52 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Elicio Therapeutics Inc.

    S-3/A - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/12/26 4:34:22 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACNT
    $ADD
    $ARBB
    $ASST
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Strive Announces the Completion of Semler Scientific Acquisition

    DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST) ("Strive") today announced the successful completion of the previously announced acquisition of Semler Scientific. Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally. Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy's initial focus will be on Strive's intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.  Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Ba

    1/16/26 8:40:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vince Holding Corp. Provides Holiday Sales Results

    Holiday Period Total Net Sales Increased 5.3% vs. Last Year Led by 9.7% Growth in Direct-to-Consumer Segment Vince Holding Corp., (NASDAQ:VNCE) ("VNCE" or the "Company"), a global retail platform, today announced sales for the nine-week holiday period ended January 3, 2026. Holiday Sales Highlights (Unaudited Results for Nine-Week Period Ended January 3, 2026) Total company net sales increased 5.3% compared to the prior year period Direct-to-Consumer segment sales increased 9.7% compared to the prior year period Wholesale segment sales decreased 2.7% compared to the prior year period Brendan Hoffman, Chief Executive Officer of VNCE commented, "Our direct-to-consumer segment

    1/12/26 7:00:00 AM ET
    $VNCE
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ACNT
    $ADD
    $ARBB
    $ASST
    Financials

    Live finance-specific insights

    View All

    Li Auto Inc. Announces Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Quarterly total revenues reached RMB28.8 billion (US$4.1 billion)1Quarterly deliveries were 109,194 vehiclesFull year total revenues reached RMB112.3 billion (US$16.1 billion)Full year deliveries were 406,343 vehicles BEIJING, China, March 12, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. ("Li Auto" or the "Company") (NASDAQ:LI, HKEX: 2015)), a leader in China's new energy vehicle market, today announced its unaudited financial results for the quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter of 2025 and Full Year 2025 Total deliveries for the fourth quarter of 2025 were 109,194 vehicles, representing a 31.2% year-over-year decrease.              FY 2025

    3/12/26 4:30:00 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Strive Adds $50M of STRC to its Corporate Treasury

    Strategy Inc (NASDAQ:STRF, LuxSE: STRE)) ("Strategy") today announced that Strive, Inc. ("Strive") has allocated $50 million, representing over one-third of its corporate treasury, to STRC (Strategy's Variable Rate Series A Perpetual Stretch Preferred Stock). "We are encouraged to see innovative institutions continue integrating STRC into their treasury strategies," said Phong Le, Chief Executive Officer of Strategy. "Prevalon Energy, Anchorage Digital, and OranjeBTC have already added STRC to their corporate treasuries, and Strive is now the latest corporation to publicly announce doing so. Adoption continues to grow as more institutions recognize the role Digital Credit can play in mode

    3/11/26 9:00:00 AM ET
    $ASST
    $MSTR
    $STRC
    Computer Software: Prepackaged Software
    Technology
    Wholesale Distributors
    Industrials

    Strive Announces SATA Enhancements and Purchase of Bitcoin & STRC

    DALLAS, March 11, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST, SATA)) ("Strive" or the "Company") today announced the following updates: SATA dividend rate increased by 25 bps to 12.75%. Dividend declared of $1.0625 per share of SATA Stock to stockholders of record the close of business on April 1, 2026, payable on April 15, 2026Targeted SATA price range narrowed to $99-$101 from $95-$105Updated guidance to not issue SATA via ATM or follow-on offerings below $100.00Purchased 179 additional Bitcoin since last filing and now holds approximately 13,311 BTCPurchased $50 million (500,000 shares) of Strategy Variable Rate Series A Perpetual Stretch Preferred Stock (NASDAQ:STRC)SATA divid

    3/11/26 8:00:00 AM ET
    $ASST
    $STRC
    Computer Software: Prepackaged Software
    Technology
    Wholesale Distributors
    Industrials

    $ACNT
    $ADD
    $ARBB
    $ASST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

    SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 8:09:56 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care